Yoshinori Hasegawa
Yoshinori Hasegawa, Izumisano-Shi JP
Patent application number | Description | Published |
---|---|---|
20110059212 | METHOD FOR PRODUCTION OF DEFATTED SOYMILK PEPTIDE - Disclosed is a method for improving the filtering properties of a defatted soymilk peptide. Also disclosed is a defatted soymilk peptide having improved filtering properties. The filtering properties of a defatted soymilk peptide can be improved by adding a calcium salt to the defatted soymilk peptide in an amount of 0.6 wt % or more in terms of calcium content relative to the crude protein content. The resulting mixture is filtered once or more times to produce a defatted soymilk peptide having improved filtering properties. The defatted soymilk peptide is characterized by containing a calcium salt in an amount of 0.4 wt % or more in terms of calcium content relative to the crude protein content. | 03-10-2011 |
Yoshinori Hasegawa, Shiga JP
Patent application number | Description | Published |
---|---|---|
20100136314 | DOPANT HOST AND PROCESS FOR PRODUCING THE DOPANT HOST - A dopant host containing, in terms of mole %, 20 to 50% SiO | 06-03-2010 |
20110192878 | GLASS ROLL AND METHOD OF PROCESSING GLASS ROLL - A roll-to-roll apparatus reliably reduces breakage of a glass film even in a case of sequentially performing predetermined processing on the glass film. Provided is a glass roll ( | 08-11-2011 |
20130129987 | METHOD OF MANUFACTURING A GLASS ROLL - A method of manufacturing a glass roll, includes: a forming step (S | 05-23-2013 |
Yoshinori Hasegawa, Nagoya JP
Patent application number | Description | Published |
---|---|---|
20090263818 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 10-22-2009 |
20110151474 | METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 06-23-2011 |
Yoshinori Hasegawa, Otsu-Shi JP
Patent application number | Description | Published |
---|---|---|
20110217521 | GLASS ROLL, AND METHOD OF MANUFACTURING GLASS ROLL - To manufacture a roll body (glass roll) of the glass film, which is subjected to a tension application, and is free from looseness, without adversely affecting the formation of the glass film and causing a problem such as cracks, provided is a method of manufacturing a glass roll ( | 09-08-2011 |
20120015132 | Sheet roll and sheet-like coupling member - A sheet roll ( | 01-19-2012 |
Yoshinori Hasegawa, Osaka JP
Patent application number | Description | Published |
---|---|---|
20120157395 | ANTI-INFLAMMATORY AGENT FOR ORAL APPLICATION, AND ANTI-INFLAMMATORY PEPTIDE FOR ORAL APPLICATION - Disclosed are a composition having an anti-inflammatory function and a therapeutic method using the composition, both of which are effective for inflammatory diseases such as inflammatory bowel disease. Specifically disclosed are: an anti-inflammatory functional agent for oral application, which comprises a soybean peptide, wherein the soybean peptide contains fractions each having a molecular weight of 500 or less and excluding any free amino acid in an amount of 40 wt % or more and has a free amino acid content of 7 wt % or less; and a therapeutic method using the anti-inflammatory functional agent. More specifically disclosed are: a novel tripeptide which comprises the following amino acid sequence: phenylalanine-leucine-valine or valine-proline-tyrosine and has an anti-inflammatory function; an anti-inflammatory composition for oral application, a medicinal agent and a feed, each of which contains the novel tripeptide as an active ingredient; and a method for treating inflammatory bowel disease using the novel peptide. | 06-21-2012 |
Yoshinori Hasegawa, Otsu-City JP
Patent application number | Description | Published |
---|---|---|
20140141258 | DOPANT HOST - A dopant host containing, in terms of mole %, 20 to 50% SiO | 05-22-2014 |
Yoshinori Hasegawa, Nagoya-Shi JP
Patent application number | Description | Published |
---|---|---|
20140363832 | MOLECULAR MARKER FOR THE EARLY DETECTION OF MALIGNANT PLEURAL MESOTHELIOMA AND THE METHODS OF ITS EXPRESSION ANALYSIS USING BLOOD AND PLEURAL EFFUSION SAMPLES - The present invention provides a method for testing mesothelioma comprising a step of determining a concentration of a human periostin protein in at least one type of sample of blood or pleural fluid of a subject. In the step of determining the concentration of human periostin protein, an antibody directed against human periostin protein may be used. The present invention further provides a kit for diagnosing mesothelioma, said kit comprising an antibody directed against human periostin protein. In the kit for diagnosing mesothelioma, the antibody directed against a human periostin protein may be an antibody that binds to a polypeptide consisting of an amino acid sequence set out in SE ID NO: 2. | 12-11-2014 |
Yoshinori Hasegawa, Kyoto-Shi JP
Patent application number | Description | Published |
---|---|---|
20150071861 | POLYMER, CONTRAST AGENT FOR NUCLEAR MAGNETIC RESONANCE ANALYSIS OR MAGNETIC RESONANCE IMAGING USING THE POLYMER, COMPOUND AND METHOD OF NUCLEAR MAGNETIC RESONANCE ANALYSIS AND METHOD OF MAGNETIC RESONANCE IMAGING USING THE POLYMER - As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a | 03-12-2015 |